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Introduction: Therapeutic education is expanding in the management of Alzheimer’s disease (AD) patients. Several
studies have revealed a positive impact of therapeutic educational programmes on the caregiver’s burden and/or
quality of life. However, to date, no study has evaluated its impact on the quality of life of the AD patient.
Methods: The THERAD study (THerapeutic Education in Alzheimer’s Disease) is a 12-month randomised controlled
trial that started in January 2013. This paper describes the study protocol. THERAD plans to enroll 170 dyads
(AD patient and caregiver) on the basis of the following criteria: patient at a mild to moderately severe stage of AD,
living at home, receiving support from a family caregiver. The main outcome is the patient’s quality of life assessed
by the Logsdon QoL-AD scale at 2 months, reported by the caregiver. The study is being led by geriatricians trained
in therapeutic education at Toulouse University Hospital in France. To date, 107 caregiver/patient dyads have been
recruited.
Conclusion: This is the first trial designed to assess the specific impact of a therapeutic educational programme on
the AD patient’s quality of life. The final results will be available in 2015.
Trial registration: [ClinicalTrials.gov: NCT01796314] Registered 19 February 2013Introduction
Therapeutic education in the care of Alzheimer’s disease
(AD)-affected patients has only recently been instigated
[1-8]. Indeed, it seems difficult to implement such pro-
grammes because of the following two characteristics of
the disease: memory loss and anosognosia. The patient’s
abilities to acquire skills and modify his/her behaviour
are often deeply affected by the disease. The caregiver,
who bears a substantial burden that can have adverse
effects on his/her physical and mental health, conse-
quently appears to be the real beneficiary of those ap-
proaches [5,6]. For this reason, most of the studies in
the field of therapeutic education in AD have focused on
the impact of therapeutic educational programmes on
the caregiver’s outcomes [2,4-8]. Several works have
demonstrated positive results, such as an improvement* Correspondence: villars.h@chu-toulouse.fr
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unless otherwise stated.in the caregiver’s quality of life (QoL) [7] and a decrease
in their depression [5,6] and burden [2]. As regards the
AD patient, a few studies have evaluated the effective-
ness of psychoeducational interventions on his/her be-
haviour [9], functional autonomy [3] or cognitive status
[1]. The large majority of studies have evaluated multidi-
mensional interventions including educational activities
(associated, as appropriate, with respite, psychological
support and/or pharmacological treatment). Two trials
showed that this type of multidimensional intervention
decreases the behavioural and psychological symptoms
of dementia [9,10].
A meta-analysis suggests that the most effective inter-
ventions for both patient (behavioural and psychological
symptoms of dementia) and caregiver (burden) are those
with an intensive psychoeducational programme for
caregivers accompanied by a follow-up [11]. In a litera-
ture review [12], four studies demonstrated positive re-
sults of combined intervention programmes including
psychoeducational components on both patients andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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health of the AD patient was improved [13,14] and ad-
mission to long-stay care was delayed [15,16]. Lastly,
among more recent studies, the Danish Alzheimer Inter-
vention Study randomised controlled trial conducted in
Denmark has demonstrated that a psychosocial counsel-
ling and support programme for outpatients with mild
AD and their primary caregivers leads to a small, al-
though nonsignificant, difference in the patient’s depres-
sion (assessed by the Cornell depression scale score [17])
in the intervention group [1].
These studies have not specifically studied the patients’
QoL as an outcome – except for the Danish Alzheimer
Intervention Study, but its intervention was not exclu-
sively educative – and were not methodologically de-
signed for this purpose. In the Therapeutic Education in
Alzheimer’s Disease (THERAD) study we chose to
evaluate the impact of an educational programme on the
AD patients’ QoL, given the results in the literature and
those of a feasibility study we have conducted. QoL
seems to be a global and relevant criterion that meets
the overall objectives of any therapeutic educational ac-
tion in the care of dementia as well as in most chronic
diseases [18,19]. However, the validity of self-reported
QoL assessments for demented patients is a critical issue
[20]. Many questions have been raised about the ability
of patients with dementia to estimate their QoL [20].
For this reason, self-rating of the QoL is replaced by
proxy rating in a large majority of clinical trials involving
AD patients, and can be considered a valid outcome
[19,21,22]. In the THERAD study, we also chose to use
the caregiver’s rating of the QoL. We will also raise the
reasons for our choice in the Discussion. It has been
shown that a multidimensional approach including, but
not involving only, therapeutic education could improve
the AD patient’s QoL [23].
For all these reasons, it was reasonable to assume that
a better understanding of the disease by the family care-
giver can have a positive impact on his/her coping strat-
egies and indirectly on the AD patient’s QoL. We
therefore designed the THERAD study. The trial ad-
dresses community-dwelling patients suffering from
mild to moderately severe AD who receive support from
a family caregiver. This paper describes the study proto-
col. In our opinion, when attempting to support the pa-
tient/caregiver dyad in AD, therapeutic education is
expected to be an especially effective tool, as well as in
many chronic diseases [24,25].
Methods
Study design
The THERAD study is a monocentric, randomised,
single-blind, controlled trial and has been registered on
clinicaltrials.gov since 19 February 2013 [ClinicalTrials.gov: NCT01796314]. The AD patient/caregiver dyads in
the intervention group receive a therapeutic educational
programme and the dyads in the control group benefit
from usual care. The THERAD study will enrol 170
dyads, 85 in the intervention group and 85 in the con-
trol group. The entry and follow-up procedures are illus-
trated in Figure 1. The study protocol was approved by
the French Ministry of Health. Informed consent was
obtained from all enrolled participants. The Toulouse
University Hospital has delivered ethical approval. Blind-
ing of raters is performed in a single-blind experimental
design: participants know the full facts (group session),
but not the experimenters. The randomisation was done
with STATA® Version 11.0. We performed a blocked
randomisation. We used a block of four, of fixed size,
without stratification. The allocation procedure was
conducted by the Department of Epidemiology of the
Toulouse University Hospital in Toulouse, France. The
randomisation list is printed and kept in this depart-
ment, protected by a password. At enrolment, a fax is
sent by the THERAD study group to this department,
together with the participant code and information re-
garding assignment. The investigators are unaware of
the randomisation list. The assignment is concealed for
the raters at follow-up visits.
Participants
AD patients suffering from mild to moderately severe
stages of the disease and their primary caregivers are eli-
gible for inclusion. The diagnosis of AD is based on the
clinical criteria of AD according to the Diagnostic and
Statistical Manual of Mental Disorders (fourth edition)
[26]. Each patient undergoes magnetic resonance im-
aging or a computed tomography scan and biological
tests. We are targeting mild to moderately severe stages
of the disease defined by the Mini-Mental Score Exam-
ination score [27], with scores of 26 to 11/30. We are
enrolling community-dwelling patients receiving support
from a family caregiver. The caregiver is defined as a
nonprofessional person living with the patient or provid-
ing support to him/her at least three times a week or for
8 hours a week. Patients of both sexes with no age limit
are eligible. Participants are being recruited from the
memory clinic and the geriatric units of the Toulouse
University Hospital in France. The inclusion period
began in January 2013, with an expected duration of
18 months. To date, 107 dyads have been enrolled.
Sample size
We hypothesise a similar QoL score in the two groups
at baseline, 25 ± 5.5 points (Logsdon Quality of Life in
Alzheimer’s disease (QoL-AD) scale including 52 points
[28]). To detect an increase of 5% in the total score and
a relative variation of more than 10% of the baseline
Preliminary visit:
Pre-screening of potential patients affected with mild to
moderately severe Alzheimer’s disease living in the 
community and receiving support from a family 
caregiver
Inform patient and caregiver about the THERAD Study
Baseline visit (screening, inclusion, randomization)
Agreement to participate
Clinical examination and Comprehensive Geriatric 
assessment (CGA) 
Assessment of judgement criteria Screen for eligible 
criteria
Enrol and randomly allocate to intervention or control
group (n=85 each)
Intervention arm, group A (n=85) Control arm, group B (n=85)
Patient pre-screening and
selection
Exclude: patients withno caregiver,
institutionalised patients, patients
included in another study
Exclude: severely affected patients
(MMSE <11), caregiver providing
less than 8 hours per week, or 3
times a week. 
M6 Visit:  Assessment of Judgment criteria +CGA
M12 Visit: Assessment of Judgment criteria + CGA
M0 Visit = Assessment of Judgment criteria
+ Comprehensive geriatric assessment (CGA) 





Collective session 1 (S1)
Educational process
assessment
Collective session 2 (S2)
Collective session 3 (S3)
Collective session 4 (S4)
Figure 1 Entry and follow-up procedures of the THERAD study. MMSE, Mini-Mental State Examination; THERAD, Therapeutic Education in
Alzheimer’s Disease.
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beta risk of 20%, and anticipating 20% attrition, 85 dyads
are required per group. The total sample size required
for the study is 170 dyads (85 per arm).Primary outcome measure
Our primary outcome measure is a change in the pa-
tient’s QoL at 2 months, determined by the Logsdon
QoL-AD scale, assessed by the primary caregiver [28].
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multidimensional criterion that can be assessed by vali-
dated tool. We chose the Logsdon QoL-AD scale be-
cause it has been validated in our population [29]. This
scale can be completed by the patient or the caregiver.
Considering that self-report could be difficult for mild
to moderately severe AD patients, we chose to use
hetero-evaluation by the caregiver as primary outcome,
as in many clinical trials involving AD dyads and target-
ing the patient’s well-being [30]. The caregivers are
instructed to carry out the rating of the QoL according
to the instructions for interviewers provided by Logsdon
and colleagues [28]. They are asked to fill in the scale as
a self-administered 13-item questionnaire, concerning
their relative’s QoL. We tried to minimise the risk of an
experimenter’s bias by using a method of collection of
data that does not require active involvement of an
interviewer.
Nevertheless, we are collecting the self-assessed Logs-
don QoL-AD as a secondary outcome.
Secondary outcome measure
The secondary endpoints are: the frequency and severity
of the patient’s behavioural and psychological symptoms
of dementia assessed by the NeuroPsychiatric Inventory
[31]; the patient’s functional autonomy assessed by the
Activities of Daily Living scale [32] and the Instrumental
Activities of Daily Living scale [33]; the patient’s QoL
assessed by the Logsdon QoL-AD scale, self-reported;
the primary caregiver’s burden assessed by the Zarit Bur-
den Inventory [34]; the primary caregiver’s QoL assessed
by the Nottingham Health Profile [35]; and the primary
caregiver’s mood assessed by the mini-Geriatric Depres-
sion Scale [36].
We are collecting these data at 2 months, 6 months
and 12 months. Lastly, we are collecting information on
factors that can influence QoL, as demonstrated in the
literature, such as acute disease for both the patient and
his/her primary caregiver, change in home care support,
hospitalisation or institutionalisation [37].
Detailed study scheme
The entry and follow-up procedures are illustrated in
Figure 1.
All visits are being performed by geriatricians who are
hospital practitioners trained in therapeutic education.
Written agreement to participate is being obtained from
all participants (patients and caregivers).
The baseline visit (M0) concerns both the patient and
the caregiver. In both the intervention group (group A)
and the control group (group B), the patient receives a
consultation led by a geriatrician. This includes a clin-
ical examination and comprehensive geriatric assess-
ment (Mini-Mental Score Examination, weight, one-legbalance, sensorial impairment, co-morbidities, pharmaco-
logical and nonpharmacological therapies) [38]. The out-
comes concerning the patient are assessed at baseline by:
Logsdon QoL-AD reported by the primary caregiver and
patient; and the Activities of Daily Living, the Instrumental
Activities of Daily Living and the NeuroPsychiatric
Inventory reported by the caregiver. The secondary out-
comes concerning the caregiver are assessed by the
mini-Geriatric Depression Scale, the Zarit Burden Inter-
view and the Nottingham Health Profile, self-reported.
At the end of the baseline visit, each patient/care-
giver dyad is randomly allocated to group A or group
B (Figure 1). The random number is generated by a com-
puterised generator using block randomisation. The block
size is concealed from all researchers. As described in the
intervention section and in Figure 1, at the end of the
baseline visit the dyads of the intervention group (group
A) receive the first step of the intervention: the educa-
tional diagnosis (cf. Intervention).
The second 2-month visit (M2) also involves the dyads
of both groups A and B, but the first part differs be-
tween groups. As described in Intervention, at the begin-
ning of M2 the participants in the intervention group
(group A) benefit from the last part of the intervention
and its assessment. The participants of both groups then
receive a clinical examination, comprehensive geriatric
assessment and assessment of endpoints.
Participants in groups A and B receive a follow-up
visit at 6 months and at 12 months, including the assess-
ment of the primary and secondary endpoints.
Intervention
The intervention consists of a therapeutic educational
programme. The total duration of intervention is 2 months.
The intervention is composed of two individual sessions
(M0 and M2) (for both patients and caregivers) and four
group sessions (for caregivers only) between M0 and M2.
The first individual session – the educational diagnosis –
takes place at the end of M0. Indeed, the educational diag-
nosis is the first step of any educational process [39,40]. Via
this specific stage, the educational team can better under-
stand the different aspects of the patient’s personality and
life history, and those of the caregiver as well. This stage al-
lows the team to identify their needs, assess their potential
and consider their requests. Its major purpose is to help the
dyad to formulate a project by identifying skills to acquire
or strengthen and defining realistic goals to reach [40]. The
patient participates in this individual session because it is
important to collect their representations and beliefs about
the disease, which are useful for the educational process of
the dyad. As a matter of fact, many people with dementia
do not have the opportunity to raise their concerns once a
diagnosis is made, and often feel isolated [41]. The AD pa-
tient’s educational diagnosis is supported by a specific tool,
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is a booklet specifically designed for patients. It is per-
formed as a semi-directive interview with patient-centred
communication techniques, and educational techniques.
The patient can also note his/her thoughts about daily life
in the booklet. This educational diagnosis is then linked
with that of the caregiver so that the team can establish a
semi-tailored plan with learning priorities for the caregiver
depending on the patient’s educational diagnosis (for
example, to adapt his/her communication style in stressful
situations). The intervention is supported by the use of a
monitoring scheme established at this step, used during the
follow-up sessions. Indeed, therapeutic patient education is a
continuing process adjusted to disease course and patient
lifestyle. A formal document is delivered to patients, called
the ‘Alzheimer’s Card’, also developed by the French Ministry
of Health [43]. This card is kept by the patient. It includes
information on disease management (for example, name
of the family practitioner, drugs taken, telephone number
of the relatives) and provides counselling in legible and
understandable form for cognitively impaired subjects.
Then caregivers benefit from four group sessions, one
per week for a month. These sessions are conducted in
small groups (six to eight caregivers) and last 3 hours
each. They aim towards allowing people to gain better
understanding of their relative’s illness, have their con-
cerns addressed and have their feelings expressed. We
have planned four group sessions for caregivers, each
focusing on a specific aspect of the disease: Session 1
(S1) – knowledge of the disease, understanding of the
symptoms, functional abilities; Session 2 (S2) – treat-
ment (pharmacological and nonpharmacological as-
pects), behavioural and psychological symptoms of
dementia in daily living; Session 3 (S3) – managementTable 1 Educational objectives of the group sessions in the in
O
Session 1 (S1): knowledge of the disease - T
- T
- T
Session 2 (S2): pharmacological and nonpharmacological treatments.












THERAD, Therapeutic Education in Alzheimer’s Disease.of crisis situations and prevention of caregiver’s exhaus-
tion; and Session 4 (S4) – assistive devices, home care
support and care pathways. Table 1 describes the objec-
tives and topics of the group sessions.
Each session is adaptable to the objectives of the par-
ticipants in each group. The goal we intend to achieve
during these group sessions is to develop the caregivers’
coping strategies. It is also part of the educational process
to offer them emotional support.
The sessions are led by a geriatrician (S1 and S2) and
a nurse (S2, S3 and S4), both trained in therapeutic edu-
cation, in tandem with stakeholders belonging to the
geriatric department: a pharmacist (S2), a psychologist
(S3) and a social worker (S4). The pedagogic methods
and tools are those currently used in therapeutic educa-
tional programmes [40]. We use tools such as storytell-
ing or drawings that allow us to explore the subject’s
representations and worries [44]. We also use computer-
based activities and brainstorming, as commonly used in
health education.
Patients can also receive written documents, when
needed, to support the educative process delivered to
their relatives during group sessions.
After the group session, the dyads benefit from an in-
dividual visit at M2. This is the continuation of the edu-
cational process with a reformulation of their personal
objectives: ‘achieved’, ‘to reach’, ‘new goals’ and ‘acquired
skills’. We try to deliver additional advice based on this
evaluation, to both the patient and the caregiver. The
patient is interviewed, using the booklet, on his/her
well-being.
We are also collecting data regarding the participants’
satisfaction. These qualitative data are part of the educa-
tional process.tervention group of the THERAD study
bjectives
o identify the cognitive impairment of the patient in everyday life
o recognise the remaining functional abilities
o determine the nonpharmacological measures to be implemented
o understand the potential effect of pharmacological therapies
o identify behavioural and psychological symptoms of the disease
o implement nonpharmacological measures to prevent these symptoms
o identify conditions of high risk (treatment modification, concomitant
llness, change of environment, relocation)
o recognise and prevent caregiver’s burnout
o identify their resources
o understand assistive devices, respite and legal aspects raised by the
isease
o identify the resources available in crisis or emergency situations
general practitioner, specialist consultation, hospitalisation)
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Data are collected in the Access database and SAS soft-
ware (developped by the SAS institute based in Cary,
North Carolina, USA) will be used to perform the statis-
tical analysis. Intention-to-treat analysis using a linear
mixed model will be performed, adjusting for patient
(disease severity) and caregiver (burden) characteristics
and occurrence of life events that may interfere with the
patient’s QoL. Attrition of dyads has been taken into ac-
count. At the moment, at the 12-month visit, there is
less than 5% attrition. Moreover, the total sample size re-
quired for the study was calculated anticipating a risk of
20% attrition to take into account this phenomenon,
which is particularly important in our population [45].
Discussion
The THERAD study started in January 2013. To date, 107
dyads have been included. The final results will be avail-
able in 2015. By transmitting knowledge, expertise and
skills to the AD patient’s caregiver [46], we hypothesised
that the patient’s QoL can improve. QoL assessment pro-
vides a format to express whether an intervention has
made an important difference to the patient’s life, but its
measurement is a challenge in AD [20,21,28,47]. Indeed,
the abstract nature of QoL limits its use to individuals
who have the cognitive capacity to understand the con-
cept, a capacity that is gradually lost in neurodegenerative
diseases such as AD (for example, the comprehension of
the item ‘you as a whole’ or ‘you in general’) [21]. For this
reason, self-rating of the QoL is often replaced by proxy
rating. However, it has been shown that there could be dif-
ferences on QoL ratings between patients, caregivers and
theoretical models [48]. Caregivers consistently rate the
patient’s QoL lower [14,49], not only because of cognitive
function [22,50,51] but also because of the caregiver’s bur-
den or depression [22,49,50,52,53] and the patient’s de-
pressive symptoms [54]. Acknowledging the problem of
potential bias of proxy reports, we chose a proxy rating for
QoL in the THERAD study, for several reasons. Firstly, it
has been demonstrated with increasing severity of the dis-
ease that patient ratings must mostly be replaced by proxy
ratings [55,56], even if Logsdon and colleagues showed in
2002 that patients can rate their own QoL until the late
stages [28]. This last study showed that the correlation be-
tween caregiver’s rating and patient’s rating was greatest
for subjects in the middle tertile of cognitive function, and
the recruitment of our centre for the THERAD study is
mainly moderately affected patients. Then in our routine
practice we found that it was difficult to estimate the pa-
tient’s QoL with self-rating. First, the patient’s ability to
identify changes or to make choices among options in a
scale is affected by lack of insight, due to anosognosia
[30,54]. Moreover, cognitive impairment, with varying
deficits of memory, attention, judgement, insight andcommunication, influences the ability of individuals to
comprehend questions or make comparisons in com-
plex domains [47]. Then, at the moderately severe stage
of the disease, patients must receive important help
from the rater to complete the scale, which can intro-
duce a real bias – the experimenter’s bias. For all these
reasons we chose to use the caregiver’s rating of the AD
patient’s QoL. We also decided to add self-rating
methods as a secondary outcome in the THERAD study,
because it has been demonstrated that self-rating and
caregiver’s ratings are complementary and should be
treated separately [20].
During the follow-up visits, we check the influence of
the intervention on the carer’s perception of QoL by col-
lecting, at each visit, data concerning his/her burden and
depression. Indeed, burden and depression have been
pointed out to influence the caregiver’s rating of the
QoL [22,49,50,52,53]. We also collect data regarding pa-
tient’s cognition, which can also influence the caregiver’s
rating of the QoL. The intervention in itself is designed
to improve caregivers’ knowledge and to modify their at-
titude or behaviour, but not to specifically decrease their
burden or improve their mood. Furthermore, psycho-
social interventions have shown mild to modest efficacy
in mitigating caregiver burden in high-quality meta-
analyses. Many studies showed improvements in care-
giver burden-associated symptoms (for example, mood,
coping, self-efficacy) even when caregiver burden itself
was minimally improved [57]. We thus hypothesised that
the potential effect of our intervention would not be linked
to a lesser caregiver’s burden that might modify his/her as-
sessment of the patient’s QoL, but to an improvement in
the patient’s QoL itself. There are similar data regarding
patient’s depression [58] and cognitive function outcome,
on which psychoeducational interventions have not dem-
onstrated any positive impact [1]. Lastly, psychoeduca-
tional intervention providing caregiver education can
decrease behavioural and psychological symptoms of
dementia [13,59] but these symptoms have not been corre-
lated with the caregiver’s rating of the QoL [60].
The THERAD study follows a feasibility study we con-
ducted at Toulouse University Hospital between January
2010 and January 2011. This was a 12-month monocentric
quasi-experimental before and after study. The inclusion
criteria were the same as those of the THERAD study.
The main outcome was the patient’s QoL as assessed by
the caregiver. Our secondary outcomes were: patient’s
functional autonomy assessed by the Activities of Daily
Living and the caregiver’s burden assessed by the Zarit
Burden Interview. Twenty-nine dyads of AD patient/care-
giver were included. At 2 months there was a significant
increase in the patient’s QoL (24.6 ± 5.1 at M0 vs. 27.2 ±
6.0 at M2, P = 0.038). This was an encouraging result and
the first step in the development of the THERAD study.
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statistical power. Use of the caregiver’s rating of the AD
patients QoL can also be considered a limitation, in a
combined intervention programme, but this limitation ap-
pears to be minimal. Indeed the educational programme
was not specifically designed to improve the caregivers’
burden or depression, factors that have been pointed out
to influence caregiver’s perception of the patient’s QoL.
However, acknowledging this problem of proxy rating, we
chose to add self-rating methods as a secondary outcome
in the THERAD study. Moreover, it has been demon-
strated that self-rating and caregiver’s ratings are comple-
mentary and should be treated separately [20]. This
improvement in patients’ QoL was in accordance with the
evidence from the literature. As mentioned earlier, a sys-
tematic review has shown that multidimensional ap-
proaches including, but not involving only, therapeutic
education, caregiver support and respite improve the pa-
tient’s QoL [23]. In addition, it has been shown that thera-
peutic educational programmes can improve patients’
QoL in many chronic diseases [61,62].
However, our feasibility study showed no significant
differences in patients’ functional autonomy or care-
givers’ burden over time. This is also consistent with the
results in the literature. Indeed, the randomised con-
trolled AIDMA study (psycho-educational programme
assistance to caregivers of Alzheimer’s patients) [3] has
not demonstrated any positive result on the patient’s
functional independence measured by the Disability As-
sessment for Dementia [63]. In our opinion, an improve-
ment in functional autonomy did not constitute an
appropriate primary outcome measure for this type of
intervention, in the light of the disease’s evolution. This
study has, by contrast, shown an increased ‘sense of
competence’ of the caregiver measured by the Sense of
Competence Questionnaire [64]. Given the evidence
from the literature and our daily experience, we hy-
pothesise in the THERAD study that therapeutic educa-
tion of both primary caregivers and AD patients could
improve the AD patient’s QoL. If the efficacy of this type
of approach is proven, and persists in the year after in-
clusion, then it will be important to implement such
programmes in the care plan of AD patients.
Conclusion
The THERAD study is the first trial designed to assess the
specific impact of a therapeutic educational programme
on the AD patient’s QoL. By helping AD patients’ care-
givers to develop coping strategies and to increase their
knowledge of the disease, we believe that the patient’s
QoL could improve. If so, a corollary benefit would appear,
such as a reduction in hospitalisations – which are fre-
quent in this population, particularly in emergency depart-
ments [65]. The final results of this study may indicatewhether such an approach needs to be implemented in
the care plan of AD patients.
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